Business has never been better for Allergan, the maker of Botox. It had more that $1 billion in sales of the toxin in 2008 and, what's more important, it is the only chemical anti-wrinkle therapy allowed in the US. The only drug that's more profitable is Pfizer's Viagra, which had $1.8 billion in sales in 2009.
肉毒素的制造商愛力根公司的生意從來沒有這么紅火過。2008年，它售出了超過10億美元的肉毒素。更重要的是，這是唯一一種被允許在全美經銷的化學抗皺療法。比它更賺錢的藥品只有輝瑞制藥公司出品的偉哥，其在2009年的銷售額達到了18億美元。

But the success of Viagra and Botox cannot hide the worry lines on the face of the pharmaceutical industry. The old strategy of finding chemical solutions to diseases is in trouble. Despite huge increases in spending, "Big Pharma" is finding it increasingly difficult to create successful drugs, or "blockbusters".
但是偉哥和肉毒素的成功并不能掩蓋制藥業面臨的憂患。使用化學藥劑治療疾病的老辦法行不通了。盡管支出大幅增加，“制藥巨頭們”還是發現要研發出成功的“靈丹妙藥”是越來越難了。

The future lies in biotechnology. Unlike traditional drug development based on chemicals, biotechnology can create entire proteins, often similar to those found in the human body.
未來是生物科技的天下。和基于化學物質的傳統制藥方法不同，生物科技能夠創造出所有蛋白質類而且通常和人體內發現的蛋白質相似。

Pfizer and Novartis have formed their own biotech divisions, and Allergan will surely follow. In the meantime, managers at the firm may develop a few frown lines themselves, now that the French pharmaceutical group Ipsen and its American parter Medicis have applied to the US Food and Drug Administration for approval of Reloxin, a botulinum toxin type A product. 輝瑞和諾華制藥已經設立了各自的生物科技部門，愛力根也一定會緊跟其后。與此同時，這家公司的管理人員們的臉上可能會增添幾條皺紋，因為法國制藥集團易普森和它的美國合作伙伴梅迪西斯公司已經向美國食品和藥物管理局申請批準Reloxin——一款A型肉毒桿菌制品。

Move over, Botox.
該讓位了，肉毒素。